Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology
•
Hematology
•
Benign Hematology
•
Von Willebrand
How do you manage bleeding or peri-procedural care for vWD patients whose vWF levels have increased or normalized from age or hormonal contraceptive use?
How do you think about removing the vWD diagnosis if levels have normalized from age?
Related Questions
Is there any benefit to using desmopressin over vWF replacement therapy for vWD?
For von Willebrand type 2B, do you expect a decline in platelet count over time as vWF increases with age?
How do you manage hemophilia A carriers with no history of bleeding complications but with mildly low factor VIII activity (6-40%)?
In light of the Haven 7 trial results, what considerations should be made regarding the monitoring and management of potential long-term adverse effects of emicizumab in infants?
How do you decide between HSCT and immunosuppressive therapy for treating hepatitis associated aplastic anemia?
Do you use direct oral anticoagulants to treat port-a-cath related VTE in patients with an active malignancy?
How would you manage aplastic anemia refractory to multiple agents?
How quickly do you expect iron stores to decrease after starting iron chelators?
What experience have you had with familial clustering of polycythemia vera?
Would you consider continuing or re-trialing hydroxyurea for sickle cell patients after development of a leg ulcer?